A Randomised, Double-blind, Placebo-controlled, Single-centre Phase IIb Trial as Part of the EU-funded UNISEC Project to Assess the Immunogenicity and Safety of Different Formulations and Dosing Regimens of FLU-v Vaccine in Healthy Adults
Latest Information Update: 07 Apr 2022
At a glance
- Drugs FLU-v (Primary) ; Montanide ISA-51
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors SEEK
- 10 Mar 2020 Primary endpoint has been met. (Percentage of Responders on Day 42 and Day 180 for IFNgamma Secretion by PBMCs)
- 10 Mar 2020 Primary endpoint has been met. (Percentage of CD4+ TH1 Cytokine Responders)
- 10 Mar 2020 Results published in the Annals of Internal Medicine